HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%

MT Newswires Live15:21

HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.

The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.

After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.

CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.

The company's shares were down by 3% in recent trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485284990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 15:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485284990","market":"sg","top_or_hot":-1,"title":"HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%","media":"MT Newswires Live","content":"<html><body><p> HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.</p><p>The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.</p><p>After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.</p><p>CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.</p><p>The company's shares were down by 3% in recent trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 15:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse....</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0456854461.SGD","symbol_name":"JPMorgan Funds - Global Natural Resources A (acc) SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485284990","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485284990","pubTimestamp":1732260110,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HUTCHMED   FRUZAQLA , its metastatic colorectal cancer  drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.After approval from Japan's Ministry of Health, FRUZAQLA became the first oral targeted therapy for metastatic colorectal cancer  in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.The company's shares were down by 3% in recent trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0456854461.SGD":"JPMorgan Funds - Global Natural Resources A (acc) SGD","BK1588":"回港中概股","CRC":"加州资源","BK1191":"制药","00013":"和黄医药","BK4213":"石油与天然气的勘探与生产","LU0266512127.USD":"摩根大通环球自然资源 A(acc)","BK1587":"次新股"},"translate_title":"和黄医药（中国）将与武田在日本推出口服结直肠癌药物；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"CRC":1},"content_text":"HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.The company's shares were down by 3% in recent trading.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485284990"}